Thomas A. Ban
Neuropsychopharmacology in Historical Perspective.

Education in the field in the Post-Psychopharmacology Era

Collated 34


Thomas A. Ban: Lithium in Psychiatry in Historical Perspective


3. Verification

Mogens Schou: My Journey with Lithium, presented by Johan Schioldann




Mogens Schou: My journey with lithium

Paul Grof’s comment

Janusz Rybakowski’s comment


Mogens Schou: My journey with lithium*


          I was born in Copenhagen on 24 November 1918 as second child of Margrethe Schou, née Brodersen (1887-1960), and Hans Jacob Schou, M.D. (1886-1952). Having graduated from High School in 1936 I vacillated between studying engineering and medicine. After six months at Askov Community College - where I met my later wife Agnete Jessen - I opted for medicine, and I graduated from the medical faculty of the University of Copenhagen in 1944.

          My father was the medical director of two hospitals, one for epileptic and psychotic patients (kolonien filadelfia) and one for patients with neuroses and mild depressions (dianalund nervesanatorium). He took a special interest in manic-depressive illness. At the time patients were given supportive psychotherapy and the medications that were then available: barbiturates for mania and opium for depression. Unfortunately, both were quite ineffective. I have vivid memories of depressed patients wandering in the hospital park with bent heads and anguished faces, waiting and waiting for the depression to lift and fearing manic and depressive recurrences. It is difficult to imagine the torment of these drawn-out depressions.

          In order to study possible biochemical and physiological changes in the manic-depressive patients my father established a research laboratory. He was very impressed by the longitudinal and extremely careful studies carried out by the Norwegian psychiatrist Rolv Gjessing who followed the nitrogen balance in patients suffering from periodic catatonia. Manic-depressive illness has also a periodic course and might reveal related biochemical changes. My father further shared the notion of a biological basis of moods and mood disorders with his countryman, the physiologist and neurologist Carl Lange. The fact that his 12 years older cousin, August Krogh, a Nobel laureate, was professor of zoophysiology, may also have been a factor.

          In 1938-39 my father spoke to me with exhilaration about the advent of electroconvulsive therapy. Here was finally something that worked:  within weeks both manias and depressions were brought to an end. When recurrences developed, electroconvulsive therapy was administered again, but the treatment was not given during symptom-free intervals.

          Following my father’s example, I trained in psychiatry and took three to four years of clinical psychiatry at Danish, Norwegian and Swedish hospitals. Because at that time the only effective treatment for mood disorders was electroconvulsive, I decided to turn to research. So, after having finished my clinical training, I studied experimental biology with Herman Kalckar in Copenhagen and Heinrich Waelsch in New York. In Kalckar's laboratory of cytophysiology I studied xanthopterin, a compound from butterfly wings with interesting chemical features. Waelsch worked at the New York State Institute of Psychiatry at Columbia University. He was a pioneer in neurochemistry, was brilliant and dynamic, and he taught me the experimental approach.

          Among my professional mentors I count with gratitude Erik Strömgren, professor of psychiatry at Aarhus University and medical director of the psychiatric hospital at Risskov. He was a remarkable man, respected in international as well as in Danish psychiatry for his erudition and clarity of thought. Rather than taking a more prestigious chair in Copenhagen he chose to build up the Risskov hospital as a comprehensive psychiatric institution with clinical and research units (Schioldann and Strömgren 1996). He created a position for me as research associate and I founded and headed a laboratory of biological psychiatry and psychopharmacology. For some years I was associate professor of psychopharmacology at Aarhus University and in 1971 I was appointed to a newly created chair of biological psychiatry.

          In 1952 (1951) Strömgren drew my attention to the Australian publications by Cade and by Noack and Trautner about the antimanic action of lithium. Here was a welcome opportunity to study a supposedly effective drug, but I felt that the studies reported until then were insufficiently stringent. I therefore devised a protocol for a trial that was partly open, partly randomized and placebo controlled (Schou, Juel-Nielsen, Strömgren and Voldby 1954). Together with two other clinicians, Niels Juel-Nielsen and Holger Voldby, Strömgren selected, treated and observed manic patients. I did not see the patients, but I threw a dice to allocate them randomly to lithium or placebo, carried out the serum lithium determinations with an old and often recalcitrant flame photometer, analyzed the data and wrote the final paper. This trial fully confirmed the antimanic effect of lithium and it was the beginning of my almost lifelong journey with the drug. Since the laboratory in Risskov could not compete with neurochemical institutes elsewhere with their surplus of expensive equipment, basic research on lithium’s mode of action did not seem a promising avenue, but Risskov offered me some special advantages. In Danish hospitals patients were diagnosed according to Kraepelinean traditions and owing to the stability of the Danish population patients could be followed for many years. Our proximity to the clinical wards had benefits. Observations made in animals, for example concerning the treatment and prevention of side effects, were sometimes directly applicable to patients; clinical observations could immediately be tested in animals, mostly white rats, by administering larger doses under more extreme conditions.

          At times my work proceeded smoothly, but I also experienced setbacks. There have been both tailwinds and headwinds on the way. By 1964 G. P. Hartigan, England (1963), P. C. Baastrup, Glostrup, Denmark (Baastrup 1964), and I (Schou 1956) had, independently of each other, made observations on small groups of patients, which seemed to indicate that prolonged treatment with lithium might ameliorate or prevent not only manic but also depressive recurrences. This was a new and unexpected observation and it called for closer examination.

          Baastrup started to give long-term lithium treatment to patients with both mania and depressions and in spite of the geographical distance between Risskov and Glostrup he invited me to cooperate with serum lithium analyses and methodology. We carried out a trial that ran over six and a half years and involved 88 bipolar and unipolar patients. These had been selected for having had two or more episodes within the last year or one or more episodes per year for the last two years. The Archives of General Psychiatry published our paper (Baastrup and Schou 1967) which revealed several things. Firstly, the start of long-term lithium treatment was associated with a remarked 87% drop in the frequency of both manic and depressive recurrences. Secondly, the recurrences that did occur usually developed after the patients had stopped taking lithium, or in patients with atypical manic-depressive disorder, mostly schizoaffective disorder. Thirdly, the efficacy of lithium did not disappear with time or after interruption and subsequent resumption of the treatment. And finally, the prophylactic effect of lithium was equally good in unipolar and bipolar patients.

          The outcome of this trial gave Baastrup and me an intense feeling of fulfillment. For the first time we had come upon a maintenance treatment that could break the almost inexorable development of recurrences and could stabilize the mood of patients who previously had suffered frequent and destructive attacks of mania, depression or both. Our patients were seriously ill; no less than 40% of them had attempted suicide before they were given lithium.

          After publication of this study it became customary to talk about prophylactic or recurrence–preventive treatment of mood disorders. The terms mood stabilization and mood stabilizers were not used until after 1990 and the users of these terms did not always specify whether they referred to prevention of manic or depressive recurrences. Lithium prevents both manic and depressive episodes.

          Psychiatrists in Denmark and other countries then began to use lithium prophylactically. They confirmed our findings and were gratified with lithium’s efficacy. However, psychiatrists from the Maudsley Hospital in London (Blackwell and Shepherd) expressed their skepticism forcibly and they did it in The Lancet, i.e., a journal other than the one in which we had published. They were not skeptical because they failed to confirm our findings, for they never tried to give lithium to patients. Their skepticism was purely speculative.

          Blackwell and Shepherd (1968) felt that the evidence did not support our claims of a prophylactic lithium action. They argued that some of the patients had a “fragmented” rather than a recurrent course of illness; that the follow-up period had been too short; that the chosen statistical method weighted the facts in favor of the hypothesis; and, finally, that the non-blind evaluation of the recurrences was biased. This led to somewhat heated discussions between them and us, and the disagreement involved both methodological and personal issues. Lader (1968) argued that the patients selected for having had frequent episodes for some years must be expected to have fewer episodes during the following years. In our refutation (Baastrup and Schou 1968a,b) Baastrup and I went over the first paper's many misunderstandings and erroneous calculations. We also repeated that most of the patients had been discharged after they were given lithium; it was the general practitioners who decided when there had been a recurrence and we had no influence on this. We furthermore pointed out that the frequency of recurrences could not be expected to drop but rather to rise year by year in the way that is characteristic of the course of recurrent affective disorders (Angst and Weis 1969; Angst, Grof and Schou 1969).

          The disagreement between us and our critics involved important methodological issues. Shepherd was one of the first psychiatrists in Great Britain to use randomized, placebo-controlled trials and he was convinced that valid evidence could be obtained only with this procedure and that any other evidence must be rejected. Baastrup’s and my trial was not randomized and placebo controlled. It had started, more or less, on an exploratory basis and had grown gradually. The marked change in the course of the disease of patients having had a median of nine episodes before the lithium treatment coincided with the start of that treatment and this was unlikely to be fortuitous. Psychiatrists who followed their patients longitudinally found our observations and conclusions convincing. Our critics disregarded the serious long-term prognosis of untreated bipolar disorder.

          The controversy created uncertainty among British and American psychiatrists, and they hesitated to start prophylactic lithium treatment. Baastrup and I could not help but feeling responsible for this to some extent. If we had carried out our study with a double-blind design from the beginning, matters might have taken a different turn. However, things being what they were, we had to consider carefully whether we should, after all, supplement our open study with a double-blind one in order to subject the question of prophylactic efficacy to further testing under the strictest precautions.

          We presented this and other arguments in a reply in Lancet (Lader 1968), but Blackwell and Shepherd remained skeptical and did not give lithium to their patients. They overlooked, or chose to overlook, the serious long-term prognosis of bipolar disorder not given prophylactic treatment.

          Personal issues are more difficult to analyze, but it is worthy of note that when Shepherd in 1967 heard me lecture about prophylactic lithium treatment in Germany and express gratification with the results, he immediately perceived me as a naïve and biased “believer.” The crucial point seems to have been reached when I told how my brother, who for 25 years had had depressions every spring, stopped having recurrences when he was given lithium. Shepherd obviously found that this was the final testimony of my folly and subjectivity. He referred to me as “an enthusiastic advocate.” The term “enthusiast” might refer to someone who is strongly engaged in his work, but in the given context the term “advocate” can hardly have been meant as a compliment, an advocate being seen as a person who supports only one side of a case. A scientist, on the other hand, is someone who gathers all relevant evidence and then weighs it carefully before drawing a conclusion. This is usually in the form of a hypothesis that may later be rejected, by the scientist himself or by others. I learned later (Baastrup and Schou 1968) that at Maudsley there were people who explained my position by hinting that I myself was manic-depressive and on lithium. That is not so.

          Reporting here what may appear to be a personal grudge involves a question of principle. If a reader pays attention to an author’s assumed motives and mental state, this may sharpen his critical sense. But if the reader rejects the data, arguments and conclusions of an author because he does not find his motives acceptable or does not deem his mental state sufficiently sane, science and patients might be deprived of valuable information.

          The idea of putting prophylactic efficacy to further testing under the strictest of precautions was tempting, but difficulties arose. Could Baastrup and I, who found the likelihood of a prophylactic action of lithium very high, justify a trial that meant that half of our patients would be given placebo instead of what we considered an active drug? Could we, who were responsible for the patients’ health, expose them to the risk of prolonged suffering or possibly suicide? Was consideration for the interests of manic-depressive patients in other hospitals or other countries sufficiently important to outweigh consideration for our own patients?

          I pondered these questions with personal feelings involved since my younger brother had suffered recurrent depressions every spring from the time he was 20-years-old. He had been treated with electroconvulsive therapy and antidepressants that to some extent relieved the current episodes, but the attacks came again and again. Then I started him on lithium and the disease stopped. After years of being disabled he could resume work; he and his family were able to look to the future with new hope. Could Baastrup and I subject him or others like him to a one-to-one risk of being deprived of the treatment that had altered their lives so radically?

          But a potentially interminable discussion did not serve any useful purpose. New data were needed and Baastrup and I decided to carry out a double-blind trial, but only after I had designed a trial protocol that took our special ethical problems into consideration.

          We selected about 100 patients with recurrent depressive disorder or manic-depressive disorder who had been in lithium treatment for a year or more were; they were allocated randomly to continue lithium treatment or to be switched to placebo. (At that time the concept of informed consent did not yet exist). The trial was blind to the observers, but non-blind outsiders could transfer a patient who relapsed during the trial back to lithium without telling the observers whether that patient had been on lithium or on placebo. The trial accordingly remained double-blind.

          A sequential analysis terminated the trial as soon as a statistically significant difference (p < 0.01) had been reached between the placebo-treated and the lithium-treated patients. By using such a procedure, we exposed as few patients as possible for as short a time as possible to placebo and minimized the ethical problem of giving placebo to patients who seemed to benefit from lithium treatment.

          The trial lasted less than six months (Baastrup, Poulsen, Schou et al. 1970). In the group of unipolar patients 9 out of 17 on placebo had recurrences and 0 out of 17 on lithium (p < 0.001). In the group of bipolar patients 12 out of 22 on placebo had recurrences and 0 out of 28 on lithium (p <0.00001). A trial in which we pooled our data with data from Prague and Zurich confirmed our findings (Angst, Weis, Grof et al. 1970). Michael Shepherd never commented on these studies.

          Controlled trials from Ireland, England, Scotland and North America using both open trials, discontinuation trials and prospective trials, led to the same results as our trial. The evidence of a marked prophylactic action of lithium became so strong that under pressure from a few American psychiatrists FDA acknowledged lithium as a prophylactic agent in bipolar disorder. It was taken into use worldwide and lithium became the prophylactic agent of choice. Prophylactic lithium treatment has been most helpful for many seriously ill patients.

          Over the years I have studied numerous aspects of the pharmacology, toxicology and clinical use of lithium. One of the studies dealt with the effect of prophylactic lithium treatment on artistic productivity (Schou 1979). Among the 24 artists I interviewed, six found their creativity reduced when they were given lithium, six felt no difference and 12 noted that their creativity had increased in quantity and quality as lithium prevented their barren depressions and their overactive manias that resulted in artistically valueless works.

          Other topics were the psychological and social effects of lithium treatment; treatment management and monitoring; treatment regimen; lithium effects on the normal mind; somatic and psychological side effects; the effects of lithium treatment on the function of the kidneys and other organ systems; interaction with other drugs; and acute and late effects of lithium intoxication. These studies involved both experiments on animals and clinical observations.

          Since my retirement in 1988 I have published reviews dealing with topics of current interest. The renal lithium clearance is of decisive importance for lithium’s safety and Klaus Thomsen and I have worked out measures to prevent lithium intoxications (Thomsen and Schou 1999). It was for some time thought that lithium treatment during pregnancy was teratogenic, but later studies without a biased selection have shown that the risk of fetal changes is minimal (Schou 1998).

          I have with particular interest studied and reviewed the literature about the prophylactic effects of other medications (Schou 1998, 2001). Canadian studies from recent years have shown that the efficacy of prophylactic medications depends primarily on the kind of patients treated. In patients with typical bipolar disorder, those with completely symptom-free intervals and in whom there may be bipolar disorder in the family, lithium is clearly the best prophylactic agent. In patients with atypical bipolar disorder, those with residual symptoms during the intervals, with other psychiatric disorders in the family, or with co-morbidity, some of the anticonvulsants and atypical neuroleptics are better. We should not cease to look for better prophylactic drugs, but until the superiority of a new drug over lithium has been unequivocally established, psychiatrists will serve their patients with typical bipolar disorder best by prescribing lithium.

          Lithium cannot be patented and consequently has little commercial interest. Occasionally I have been asked whether it would have been an advantage if lithium had been subsidized by the pharmaceutical industry. With such support it might have been as massively promoted as the contending drugs are and that could have been an advantage for the patients. However, the drug companies were not interested and I have had complete scientific freedom. It seems unlikely that a sponsoring pharmaceutical company would have permitted me to study and publish about adverse effects of lithium more extensively than anyone else.

          Since there is no commercial support for lithium, I myself have had to collect and disseminate information about it. I have used a database and a reprint library that I started in 1954 and have kept updated since then. I have travelled extensively and lectured to, as well as learned from, general practitioners, practicing psychiatrists, hospital physicians and patient groups around the world. It has also been interesting and rather difficult to write books in non-technical language for patients and relatives, but it has given me many contacts. The books have appeared in 12 languages, some of them in six editions. The importance of that kind of activity, now called “psychoeducation,” is being increasingly recognized.

          Although lithium is still considered the gold standard against which all newer prophylactic agents are measured, it continues to have a rather limited use. Patients and psychiatrists take it for granted that an old drug must be less efficacious than newer drugs and powerful pharmaceutical companies see inexpensive lithium as a competitor for their more expensive products. There is a dire need to inform patients and physicians about recent advances.

          It is of particular importance to inform about the evidence of a marked anti-suicidal effect of long-term lithium treatment. In affectively ill patients the frequency of suicide attempts and of completed suicides is 10-15 times (not per cent) lower in patients on lithium than in patients not on lithium (Müller-Oerlinghausen, Ahrens, Grof et al. 1992; Baldessarini, Tondo and Hennen 2001). It is surprising that lithium is not used more often in patients with severe depressive symptoms, whether they are bipolar, suffer from major depressive disorder or have schizophrenia. One could give lithium prophylactically to patients with suicidal thoughts, to patients with suicide attempts in the past and to patients with suicides in the family. In no other agent with prophylactic action in mood disorders has convincing evidence of an anti-suicidal effect been presented.

          The discovery that long-term lithium treatment has a neuroprotective effect has also increased the interest in lithium. Even if these observations have not yet led to diagnostic, prognostic or therapeutic advances, they give new hope to patients and psychiatrists.

          I admit to having often felt frustrated on my journey with lithium, but lately I have been encouraged and gratified by the increased research interest in, and use of, lithium, even in the United States.

          John Cade and Poul Christian Baastrup have been of special importance to my work and development. Cade and I met on three occasions: when he and his wife visited us in Denmark in 1972 (1970), when he and I shared the International Scientific Kittay Foundation Award in 1974 and when my wife and I visited the Cades in Melbourne the following year.  He was a mild-mannered, modest person who once said of himself: “I am not a scientist. I am only an old prospector who happened to pick up a nugget.” But prospectors find because they seek. John Cade was characterized by insatiable curiosity, keen observation, willingness to test even absurdly unlikely hypotheses and the courage to run the risk making a fool of himself.

          Poul Christian Baastrup was a friend and associate and the role he played in the development of prophylactic lithium treatment was essential. I once characterized Cade, Baastrup and myself as the artistic, the persevering and the systematic scientist, respectively. Baastrup was characterized by unusual consistency of approach and double devotion to scientific truth and the welfare of his patients. In addition to monitoring his lithium-treated patients for the rest of their lives, Baastrup gave them unceasing psychological support and this undoubtedly increased their compliance and adherence.

          I have benefited from cooperation and friendship with many other brilliant and conscientious scientists. Paul Grof from Prague, later Ottawa, and Bruno Müller-Oerlinghausen from Berlin are particularly close friends who always have given me inspiration and support. It was together with them that in 1988 I initiated an International Group for the Study of Lithium-treated (IGSLI) patients. It has had participants from Belmont, Berlin, Dresden, Freiburg, Fullerton, Halifax, Hamilton, Lübeck, Ottawa, Poznan, Prague, Risskov, Stockholm, Vienna and Zürich. Members meet once a year, rotating meeting venues, to discuss past and present joint projects.

          Bruno Müller-Oerlinghausen suggested that the mortality and suicidal behavior of lithium-treated patients should be one of the first topics to be studied. As noted above, I considered the anti-suicidal effect of lithium one of the most important advantages of prophylactic lithium treatment. Other projects initiated and headed by Paul Grof and Martin Alda, deal with so-called “excellent lithium responders,” carefully defined by IGSLI. These studies are yielding important information about the course of the disease, subtyping and prediction of response in the patients themselves and in their children.

          Why did I become so involved with mood disorders and lithium? My choice contained an element of luck, but it was not purely accidental. As already mentioned, my father took a special interest in manic-depressive illness and scientific curiosity is contagious. Then lithium came along and turned out to be efficacious - another felicitous juxtaposition of observation, circumstance and a tuned mind. I have not seen any reason to stray from the topic of lithium while there is still so much to find out.

          Perhaps more than most scientists I have been granted the privilege of reaping the fruits of my labor. A number of family members have been or are given lithium with marked effect. If prophylactic lithium treatment had not emerged, they might today have been hospitalized or dead.

          In Haiti, where voodoo is the prevailing religion, psychotic persons are believed to be “ridden” by a Loa, a spirit. Scientists engaged in their work are likewise possessed. Their Loa never leaves them in peace, rides them day and night, year after year. During my life I have been ridden, but with generosity. It has been a rewarding experience to meet so many kind and generous persons and to work in a field where many scientific interests and insights converge. It has been still more gratifying to participate in the combat of a protracted, devastating and potentially deadly illness.




Angst J, Weis P. Zum Verlauf depressiver Psychosen. In: Schulte W, Mende W (eds.): Melancholie in Forschung, Klinik und Behandlung. Stuttgart: Thieme, 1969. pp. 2-9.

Angst J, Grof P, Schou M. Lithium. Lancet 1969; I:1097.

Angst J, Weis P, Grof P, Baastrup PC, Schou M. Lithium prophylaxis in recurrent affective disorders. Br. J. Psychiatr. 1970; 116:604-14.

Baastrup PC, Schou M. Prophylactic lithium. Lancet 1968a; I:1419-22.

Baastrup PC, Schou M. Prophylactic lithium. Lancet 1968b; II:340-50.

Baastrup PC, Poulsen JC, Schou M, Thomsen K, Amdisen A. Prophylactic lithium: Double-blind discontinuation in manic-depressive disorders. Lancet 1970; II: 326-30.

Baastrup PC, Schou M. Lithium as a prophylactic agent: Its effect against recurrent depressions and manic-depressive psychosis. Arch Gen. Psychiatr. 1967; 16:162-72.

Baastrup PC. The use of lithium in manic-depressive psychosis. Compr. Psychiatr. 1964; 5:396-408.

Baldessarini RJ, Tondo L, Hennen J. Treating the suicidal patient with bipolar disorder. Reducing suicide risk with lithium. Ann. NY Acad. Sci. 2001; 932:24-38.

Blackwell B, Shepherd M. Prophylactic lithium: Another therapeutic myth? An examination of the evidence to date. Lancet 1968; I: 968-71.

Hartigan GP. The use of lithium salts in affective disorders. Br. J. Psychiatr. 1963;109: 810-14.

Lader M. Prophylactic lithium. Lancet 1968; II:103.

Müller-Oerlinghausen B, Ahrens B, Grof E, Grof P, Lenz G, Schou M, Simhandl C, Thau K, Volk J, Wolf R, et al. The effect of long-term lithium treatment on the mortality of patients with manic-depressive and schizoaffective illness. Acta Psychiatr Scand. 1992 Sep;86(3): 218-22.

Schioldann J, Strömgren LS. Erik Robert Volter Strömgren. 28 November 1909 –15 March 1993. A Bio-Bibliography. Acta Psychiatr. Scand. 1996; 94:283-302.

Schou M, Juel-Nielsen N, Strömgren E, Voldby H. The treatment of manic psychoses by the administration of lithium salts. J. Neurol. Neurosurg. Psychiatr. 1954; 17:250-60.

Schou M. Lithium ved mani: Praktiske retningslinier. Nord. Med. 1956; 55:790-4.

Schou M.: Artistic productivity and lithium prophylaxis in manic-depressive illness. Br. J. Psychiatr. 1979; 135:97-103.

Schou M. Has the time come to abandon prophylactic lithium treatment? A review for clinicians. Pharmacopsychiatry 1998; 31:210-15.

Schou M. Lithium treatment at 52. J Affect Disorders 2001; 67:21-32.

Schou M. Treating recurrent affective disorders during and after pregnancy: What can be taken safely? Drug Saf. 1998; 18:143-152Thomsen K, Schou M. Avoidance of lithium intoxications: Advice based on knowledge about the renal lithium clearance under various circumstances. Pharmacopsychiatr. 1999; 32:83-6.


*Printed in: J. Schioldann. History of the Introduction of Lithium into Medicine and Psychiatry. Birth of Modern Psychopharmacology 1949, Appendix III (pp. 312-320). Adelaide Academic Press, 2009. Danish edition: Mogens Schou: Min rejse med lithium. Selvbiografiske noter. Bibibliotek for Læger September 2005:217-228, “introduced” by J. Schioldann: [The lithium pioneer Mogens Schou – half a century with lithium]. Ibid. pp. 209-216, accompanied by a reprint of the Danish edition of Schou’s et al.’s original lithium paper, 1955 (Ugeskrift for Læger 1955;117:93-101). – Coincidentally, Mogens Schou died on 29 September 2005. - J. Schioldann. Obituary: Mogens Abelin Schou (1918-2005) – half a century with lithium. History of Psychiatry 2006;17(2):247-52.


August 30, 2018


Paul Grof’s comment


          Thank you for reprinting Mogens Schou’s “My Journey.”  Although Mogens wrote it a number of years ago, it has gained relevance as, for several reasons, lithium is regaining popularity and interest: a kind of “Lithium Renaissance.”

          One issue seems new.  Since the publication of Johann Schioldann’s  English translation of Lange’s Periodic depressions and of his observations on lithium in those conditions,  several people have recently raised a sensible question: Was Mogens Schou and Christian Baastrup ’s discovery of the stabilizing effects of lithium an original idea or, did Schou merely extend Lange’s work to  manic-depressive patients?  As in this report, “My Journey,” Mogens Schou mentions that his father knew about Lange, this question now adds on intensity.

          I am convinced that, until late in his life, Mogens did not know that Lange successfully used lithium in the long-term treatment of his “periodic depressions.”  When the extraordinary efficacy of lithium was confirmed in manic-depressive illness around 1970, some psychiatrists and historians went back and brought to light many previously unknown historical facts.  That, of course, was all the usual wisdom of hindsight.

          First of all, during the initial battle for the recognition of lithium’s efficacy, had Mogens known about Lange’s earlier findings, he would have quoted them as support and with great joy.  At that time, whenever he could find any indication that lithium was useful, he would immediately quote it.

          Second, Mogens was unusually meticulous about searching his sources.  One of the things that I hugely admired and try to emulate was that any research report, even seemingly utterly insignificant, in Mogens’ mind deserved a prudent consideration and analysis.  Initially, I thought that he was perhaps too obsessive. He would carefully analyze even reports that to me seemed irrelevant and banal. However, gradually I learned that his attention to details and minutia was well justified. This meticulousness was reflected in several ways:  for example, he insisted that he pronounce the name of any foreign author in the way it is pronounced in the author’s language.

          Third, throughout the 50 years Mogens and I had close contact, regular correspondence and frequent discussions it was crystal-clear that his primary motivation for research was to improve the life of patients. One can see particularly in his early publications in the 1970s how comprehensive he was in entirely covering literature about all the various uses of lithium.  That the prophylactic work with lithium is recognized as his own had relatively little importance for him, if any. His joy came primarily from the patients reporting how well they became.

          I think Lange’s observation about lithium may have some effect on Mogens’ thinking when it was published during his final years. The last investigation he actually designed was a study of the stabilizing effect of lithium specifically in recurrent depressions.


January 10, 2019


Janusz K. Rybakowski’s comment


          My comment on the Mogens Schou autobiography, written by Johann Schioldann, is  based on the speech I delivered in Copenhagen, November 23, 2018, when we celebrated the 100th anniversary of Mogens Schou's birthday.

          Mogens Schou was a great clinician and scientist - a true giant of lithium research and treatment.  For the establishment of contemporary lithium therapy, Mogens Schou probably achieved more than anybody in the world. There was more than a half century of his indefatigable lithium activity which he performed with great and exceptional scientific scrutiny. Among lithium researchers, Mogens Schou can be named Primus Inter Pares as he, together with his Danish colleagues, were the first to perform pivotal studies and to make important clinical observations on lithium therapy. Concomitant with this, Mogens Schou was also extremely engaged in the care of patients receiving lithium.

           The year Mogens Schou began his lithium studies, 1952, coincides with the year of the death of his father Hans Jacob Schou, a prominent Danish psychiatrist. From him, Mogens inherited a dedication to patients and to neurobiological studies of psychiatric disorders. The initial fruit of his clinical studies on lithium took place two years later, with the publication of the first controlled study on lithium’s effectiveness among patients in a manic state (Schou, Juel-Nielsen, Strömgren and Voldby 1954).  When it was performed over half a century ago, the study was kind of unusual because the researchers used a neutral preparation (placebo) for comparative purposes to show the "real" effect of lithium. The study included 38 patients in a manic state, among whom 30 had “clear” affective symptoms - a spectacular improvement was noted in 12, improvement in 15 and a lack of effect in three. During therapy, measurements of the concentration of the drug in blood serum were systematically made and in six of them in cerebrospinal fluid. It was found that concentrations of lithium ion in the serum remained within 0.5 to 2 mmol/l, which was an important element for further research on relations between the concentration of lithium in serum and its clinical effectiveness and toxic symptoms. Three years later Mogens Schou summed up in his extensive article published in the Pharmacological Reviews the whole contemporary knowledge concerning pharmacology, biochemistry and clinical effects of lithium (Schou 1957).

          The real breakthrough for the understanding of lithium’s therapeutic action in mood disorders occurred in the early 1960s when the first reports pointing to a possible prophylactic effect of lithium therapy on manic and depressive recurrences appeared. They came from England (Geoffrey Hartigan 2014) and Denmark (Paul Christian Baastrup 1964). In connection with this, Mogens Schou, together with Paul Baastrup, performed a mirror-image study of lithium prophylaxis on 88 patients with unipolar and bipolar affective disorder in Denmark’s Glostrup hospital. The trial lasted six and half years and the main finding was that the average duration of disordered mood (mania or depression) within a year before lithium was 13 weeks, while during a year on lithium it was shortened to the average of two weeks. The results were published in the Archives of General Psychiatry (Baastrup and Schou 1967).

           The next year, 1968, was marked by Mogens Schou’s important clinical observations and studies. For the first time, the adverse effect of lithium on thyroid function (goiter) was described, based on findings in a big group of 330 lithium-treated patients (Schou, Amdisen, Eskjaer et al. 1968a). Also, a study on renal handling of lithium elucidated the mechanism of renal lithium reabsorption (occurring in the proximal tubule) and its relationship to sodium reabsorption. This discovery provided a plausible explanation of lithium toxicity with sometimes fatal outcome in subjects receiving lithium as a salt substitute which occurred in turn of 1940/1950s (Thomsen and Schou 1968). And, based on eight cases, the first comprehensive description of lithium poisoning was published, with a characterization of prodromes, clinical picture and outcomes, as well as suggested management (Schou, Amdisen and Trap-Jensen 1968b).

          However, in the same year, a strong backlash against lithium prophylaxis provided by the British psychiatrists Barry Blackwell and Michael Shepherd appeared in Lancet, titled  “Prophylactic lithium. Another therapeutic myth?” The article was questioned the validity of the findings on lithium effectiveness and requested double-blind trials on this issue (Blackwell and Shepherd 1968). Fifty years after this publication, Barry Blackwell, who initiated INHN discussion on the topic with "The Lithium Controversy. A Historical Autopsy" (2014) seemed to be confident that lithium remains the best first choice for mood stabilization in bipolar disorder.

          Eight placebo-controlled trials in which Mogens Schou exercised a significant initiative were performed in Europe (in Denmark and the UK) and the USA in 1970-1973. In these studies patients were to have had at least two recurrences of illness in the two years preceding lithium treatment. Most of these studies employed a method comparing the course of illness in a group in which lithium was discontinued and replaced with a placebo with a group which continued to receive lithium (discontinuation design). Recurrence of illness was defined as a deterioration that would require psychiatric hospitalization or commencing regular antidepressive or antimanic treatment. Analysis of all research showed that the percentage of patients in whom recurrences of depression or mania occurred was significantly lower while receiving lithium (on average 30%) than while receiving placebo (on average 70%) (Schou and Thomson 1976).

          Because lithium therapy can be administered during pregnancy, Mogens Schou in 1968 helped initiate the “Register of Lithium Babies” (Schou, Goldfield, Weinstein and Villeneuve 1973). The clinical observations to-date have shown that lithium use during pregnancy by women with a mood disorder, especially by those previously treated with this drug, makes a favorable risk/benefit ratio in favor of lithium (Poels, Bijma, Galbally and Bergink 2018).

          In his promulgation of lithium therapy, Mogens Schou was very interested in how such therapy influences the various aspects of the patient’s life. As bipolar disorder is overrepresented among artists, he was the first to examine the issue of the effect of lithium prophylaxis on artistic creativity.  From 24 artists treated with lithium due to bipolar disorder, 12 reported an increase in their artistic productivity, six a slight decrease and six noted no change at all (Schou 1979).

          Schou was extremely dedicated to the best clinical practice of lithium therapy. Since 1980 there have appeared successive issues of Mogens Schou’s book Lithium Treatment of Manic-Depressive Illness, a practical guide to lithium therapy for doctors, patients and their families. Successive revised editions appeared in 1983, 1986, 1988 and 1993. The 6th edition was titled Lithium Treatment of Mood Disorders (Schou 2004).

          Mogens Schou, together with Bruno Müller-Oerlinghausen from Berlin, and Paul Grof from Ottawa were the Founding Fathers of the International Group for the Study of Lithium-Treated Patients (IGSLI), created in 1988. In the 1990s the group published seminal papers showing a favorable influence of lithium on the decrease of mortality and prevention of suicidal behaviors (Müller-Oerlinghausen, Ahrens, Volk et al. 1991; Müller-Oerlinghausen, Wolf, Ahrens 1994; Müller-Oerlinghausen, Wolf, Ahrens et al. 1996). Recently, the IGSLI publication confirmed the neuroprotective effect of lithium (Hajek, Bauer, Simhandl et al. 2014). Since its conception, the group has had yearly meetings; the most recent, the 32nd IGSLI conference, took place in Santiago, Chile. There participants could visit the Acatama Dessert, the world's largest and purest active source of lithium.

          In the years 1990-1994 the journal Lithium was published. Mogens Schou was on the editorial board and became the author of the first scientific article in the journal; it was on lithium and treatment-resistant depression (Schou 1990). After many years, lithium augmentation of antidepressants is the best evidenced pharmacological strategy in treatment-resistant depression (Bauer, Adli, Ricken et al. 2014). By some researchers, it is even regarded as the second main indication for lithium use (after preventing mood recurrences) in mood disorders.

          With the foundation in 1999 of the International Society of Bipolar Disorders (ISBD), Mogens Schou was nominated as its honorable president. Since 2001, during the society’s annual international conferences, Mogens Schou’s awards have been given for exceptional achievements in the field of research, educational activity and organizational and media activity concerning the bipolar affective disorder.

          On September 23–25, 2005, Mogens Schou participated in the 19th IGSLI conference that took place in Poznań, Poland. In spite of limitations connected with his advanced age, he was very glad that he could actively participate in this conference; during it, he presented one of his new research proposals. It concerned the issue of lithium for prophylaxis of unipolar depression where he suspected a significant efficacy, especially among so-called "hidden bipolars." Over the years, a growing number of controlled studies have been published confirming that lithium has prophylactic effectiveness in unipolar depression. Recently, it was reported from Finland, on the basis of an observational study, that lithium monotherapy is the pharmacological treatment associated with the lowest risk of psychiatric hospitalization in patients with severe unipolar depression (Tiihonen, Tanskanen, Hoti et al. 2017). There was no sign then that several days after the Poznan IGSLI conference Mogens Schou would finish his busy lithium-oriented life.

          My account of Mogens Schou spanned from 1971, when I wrote the letter to him about my interest in lithium treatment, until the IGSLI conference in Poznan in 2005 when Mogens brought me the copy of this letter as a token of our long-term acquaintance. This was a very emotional event for both of us. In the meantime, I was a Mogens’s student, visiting him on several occasions in Risskov, Denmark. Gradually, I became his partner in lithium research. The crowning achievement of this relationship was the Mogens Schou Research award I received during the International Society of Bipolar Disorder conference in Mexico City held in March 2018.



Baastrup PC, Schou M. Lithium as a prophylactic agents. Its effect against recurrent depressions and manic-depressive psychosis. Arch Gen Psychiatry 1967;16:162-72.

Baastrup P.C. The use of lithium in manic-depressive psychoses. Compr Psychiatry 1964; 5:396-408.

Blackwell B, Shepherd M. Prophylactic lithium: another therapeutic myth? An examination of the evidence to date. Lancet 1968;7549:968-71.

Blackwell B. The Lithium Controversy. A Historical Autopsy. June 19, 2014.

Hajek T, Bauer M, Simhandl C, Rybakowski J, O'Donovan C, Pfennig A et al. Neuroprotective effect of lithium on hippocampal volumes in bipolar disorder independent of long-term treatment response. Psychol Med 2014;44:507-17.

Hartigan G.P. The use of lithium salts in affective disorders. Br J Psychiatry 1963; 109:810-814.Bauer M, Adli M, Ricken R, Severus E, Pilhatsch M. Role of lithium augmentation in the management of major depressive disorder. CNS Drugs 2014;28:331-42.

Müller-Oerlinghausen B, Ahrens B, Volk J, Grof P, Grof E, Schou M, Vestergåard P, Lenz G, Simhandl C, Thau K, et al. Reduced mortality of manic-depressive patients in long-term lithium treatment: an international collaborative study by IGSLI. Psychiatry Res 1991;36:329-31.

Müller-Oerlinghausen B, Wolf T, Ahrens B, Schou M, Grof E, Grof P, Lenz G, Simhandl C, Thau K, Wolf R. Mortality during initial and during later lithium treatment. A collaborative study by the International Group for the Study of Lithium-treated Patients. Acta Psychiatr Scand 1994;90:295-7.

Müller-Oerlinghausen B, Wolf T, Ahrens B, Glaenz T, Schou M, Grof E, Grof P, Lenz G, Simhandl C, Thau K, Vestergaard P, Wolf R. Mortality of patients who dropped out from regular lithium prophylaxis: a collaborative study by the International Group for the Study of Lithium-treated patients (IGSLI). Acta Psychiatr Scand 1996;94:344-7.

Poels EMP, Bijma HH, Galbally M, Bergink V. Lithium during pregnancy and after delivery: a review. Int J Bipolar Disord 2018;6:26.

Schou M, Amdisen A, Eskjaer Jensen S, Olsen T. Occurrence of goitre during lithium treatment. Br Med J. 1968a;3:710-13.

Schou M, Amdisen A, Trap-Jensen J. Lithium poisoning Am J Psychiatry 1968b;125:520-7.

Schou M, Goldfield MD, Weinstein MR, Villeneuve A. Lithium and pregnancy. I. Report from the Register of Lithium Babies. Br Med J 1973;2:135-6.

Schou M, Thompsen K. Lithium prophylaxis of recurrent endogenous affective disorders. In: Lithium Research and Therapy, Johnson FN, editor. London: Academic Press 1976. pp. 63-84.

Schou M. Artistic productivity and lithium prophylaxis in manic-depressive illness. Br J Psychiatry 1979;135:97-103.

Schou M. Biology and pharmacology of the lithium ion. Pharmacol Rev 1957;9:17-58.

Schou M. Lithium and treatment-resistant depression. A review. Lithium 1990;1:3-8.

Schou M. Lithium Treatment of Mood Disorders. A Practical Guide. Basel: Karger; 2004.

Schou M, Juel-Nielsen N, Strömgren E, Voldby H. The treatment of manic psychoses by the administration of lithium salts. J Neurol Neurosurg Psychiatry. 1954;17:250-60.

Thomsen K, Schou M. Renal lithium excretion in man. Am J Physiol 1968;215 823-7.

Tiihonen J, Tanskanen A, Hoti F, Vattulainen P, Taipale H, Mehtälä J, Lähteenvuo M. Pharmacological treatments and risk of readmission to hospital for unipolar depression in Finland: a nationwide cohort study. Lancet Psychiatry 2017;4:547-53.


October 24, 2019

            June 4, 2020